Message From the Executive Director

Autumn 1995

As CFRI's 20th birthday arrives this November, it is appropriate to celebrate the past 20 years of progress in cystic fibrosis research. Since CFRI's incorporation in 1975, we have raised over $4.3 million dollars and funded over $3 million for CF research and educational programs! During the past 20 years in the U.S., the life expectancy of those with CF has gone from 9.2 years to 30 years! This is exciting news for everyone with cystic fibrosis and their families. We are grateful for research that has led to improved antibiotics and treatments, and a better understanding of cystic fibrosis. However, a 30-year lifespan is not long enough, and there is still work to be done.

This fall the CFRI Board of Directors is reevaluating its research agenda in order to meet the new challenges of the disease. This is a very exciting time in the field of cystic fibrosis research. When we ask for your help in fundraising for CFRI, please respond generously with your time, talents and donations.

Our CFRI/IACFA Conference, held August 4 - 6, 1995 in Palo Alto, was very powerful and most enlightening. Speakers included distinguished physicians, scientists and medical professionals from throughout the world. 261 participants from 15 countries shared information on how they take care of themselves and how health care is provided by their countries. Countries represented were Australia, Austria, Brazil, Canada, Denmark, England, Finland, Germany, Holland, Italy, Norway, Paraguay, Spain, Switzerland and the U.S.A. Conference presentations and panel discussions are summarized in this newsletter, and are available in their entirety for rental or purchase on video tape (see page 5 for details).

We are most grateful to the fourteen sponsors whose generosity made the CF Conference possible: American Biosystems, Inc., Cystic Fibrosis Research, Inc., Florida Cystic Fibrosis Pharmacy, Genentech, Inc., Human Resources Advertising, Inc., Invacare Corporation, Lincare, Inc., Omron Health Care, Inc., Ortho/McNeil Pharmaceutical, PARI Respiratory Equipment, Inc., Quantum Health Resources, Scandipharm, Inc., Solvay Pharma Deutschland GesMBH, and Solvay Pharmaceuticals. Thank you for helping to educate CF patients and their families around the world. We know that being informed about CF is our most powerful tool for meeting the challenges of this disease.

Sincerely,
Ann Robinson

Return to Fall 1995 Index Page